Ionic basis of pharmacological therapy in Brugada syndrome

Journal of Cardiovascular Electrophysiology

Volumn 18, Issue 2, 2007, Pages 234-240

  Márquez, Manlio F ^a   Salica, Gabriel ^a   Hermosillo, Antonio G ^a   Pastelín, Gustavo ^a   Gómez Flores, Jorge ^a   Nava, Santiago ^a   Cárdenas, Manuel ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Arrhythmic storm; Brugada syndrome; Cilostazol; Isoproterenol; Mexiletine; Quinidine; Sotalol; Sudden cardiac death; Tedisamil; Ventricular fibrillation

Indexed keywords

4 AMINOPYRIDINE; AMRINONE; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CILOSTAZOL; CLARITHROMYCIN; COLESTYRAMINE; DISOPYRAMIDE; ISOPRENALINE; MEXILETINE; MILRINONE; PHOSPHODIESTERASE III INHIBITOR; QUINIDINE; SOTALOL; TEDISAMIL;

ACTION POTENTIAL; ARRHYTHMOGENESIS; ARTICLE; BRUGADA SYNDROME; CLINICAL TRIAL; CONTINUOUS INFUSION; DEFIBRILLATOR; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEART ARREST; HEART FAILURE; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; QRS COMPLEX; SODIUM CURRENT; ST SEGMENT; ST SEGMENT ELEVATION; SUDDEN DEATH; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; ION CHANNEL GATING; ION CHANNELS; MODELS, CARDIOVASCULAR;

EID: 33846367351     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2006.00681.x     Document Type: Article

References (62)

1. Brugada P, Brugada J: Right bundle branch block, persistent ST-segment elevation and sudden cardiac death. J Am Coll Cardiol 1992;20:1391-1396.
2. Belhassen B, Viskin S, Antzelevitch C: The Brugada syndrome: Is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin Electrophysiol 2002;25:1634-1640.
3. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M: Effects of electrophysiologic-guided therapy with Class IA antiarrhytmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999;10:1313-1315.
4. Tsuchiya T: Role of pharmacotherapy in Brugada syndrome. Indian Pacing Electrophysiol J 2004;4:26-32.
5. Cárdenas M: La Clínica de las Arritmias. La Prensa Medica Mexicana: México, 1987, pp. 5-15.
6. Yan GX, Antzelevitch C: Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100:1660-1666.
7. Antzelevitch C, Brugada P, Brugada J, Brugada R: Brugada syndrome: From cell to bedside. Curr Probl Cardiol 2005;30:9-54.
8. Clancy CE, Kass RS: Defective cardiac ion channels: From mutations to clinical syndromes. J Clin Invest 2002;110:1075-1077.
9. Yan GX, Joshi A, Guo D, Hlaing T, Martin J, Xu X, Kowey PR: Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation 2004;110:1036-1041.
10. Coronel R, Casini S, Koopmann TT, Wilms-Schopman S, Verkerk AS, de Groot JR, Bhuiyan Z, Bezzina CR, Veldkamp MW, Linnenbank AC, van der Wal AC, Tan HL, Brugada P, Wilde AAM, de Baker JMT: Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome. Circulation 2005;112:2769-2777.
11. Antzelevitch C, Yan GX, Shimizu W, Burashnikov A: Electrical heterogeneity, the ECG, and cardiac arrhythmias. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology. From Cell to Bedside. Third Edition. Philadelphia: W.B. Saunders Co, 2000, pp. 222-238.
12. Roden DM: Antiarrhythmic drugs. In: Hardman JG, Limbird LE, Goodman Gilman A, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw Hill Co, 2001, pp. 933-970.
13. Méndez R, Pastelin G: Modificaciones farmacológicas de los fenomenos bioeléctricos de los tejidos y células del corazón. Gac Méd Méx 1970;100:27-40.
14. Rodríguez MI, Méndez R: Acción de la quinidina y de la procainamida sobre la excitabilidad, la conducción y el periodo refractario de los tejidos del corazón de mamífero. Arch Inst Cardiol Méx 1954;24:456-492.
15. Méndez R, Kabela E: Conceptos Actuales Sobre la Fármacoterapia de las Arritmias. III Simposio Panamericano de Farmacología y Terapéutica. Amsterdam: Excerpta Medica, 1965.
16. Méndez R, Aceves J, Kabela E: Differences among quinidine, atropine and potassium in their action on experimental arrhythmias. Acta Cardiol 1965;20:1-16.
17. Yang T, Roden DM: Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996;93:407-411.
18. Grace AA, Camm AJ: Quinidine. N Engl J Med 1998;338:35-45.
19. Imaizumi Y, Giles WR: Quinidine-induced inhibition of transient outward current in cardiac muscle. Am J Physiol 1987;253:H704-H708.
20. Antzelevitch C: The Brugada syndrome: Ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001;12:268-272.
21. Nakajima T, Kurachi Y, Ito H, Takikawa R, Sugimoto T: Anticholinergic effects of quinidine, disopyramide, and procainamide in isolated atrial myocytes: Mediation by different molecular mechanisms. Circ Res 1989;64:297-303.
22. Alings M, Dekker L, Sadee A, Wilde A: Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001;24:1420-1422.
23. Watanabe H, Chinushi M, Washizuka T, Sugiura H, Hirono T, Komura S, Hosaka Y, Yamaura M, Tanabe Y, Furushima H, Fujita S, Aizawa Y: Variable electrocardiographic effects of short-term quinidine sulfate administration in Brugada syndrome. Pacing Clin Electrophysiol 2005;28:372-377.
24. Belhassen B, Glick A, Viskin S: Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004;110:1731-1737.
25. Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, Guicheney P, DiFusco S, Rey JL, Cauchemez B, Leenhardt A: Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004;43:1853-1860.
26. Itoh H, Shimizu M, Takata S, Mabuchi H, Imoto K: A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectinally affecting blocking actions of antiarrhythmics drugs. J Cardiovasc Electrophysiol 2005;16:486-493.
27. Valdivia CR, Tester DJ, Rok BA, Porter CB, Munger TM, Jahangir A, Makielski JC, Ackerman MJ: A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovasc Res 2004;62:53-62.
28. Garg A, Finneran W, Feld G: Familial sudden cardiac death associated with a terminal QRS abnormality on surface 12-lead electrocardiogram in the index case. J Cardiovasc Electrophysiol 1998;9:642-647.
29. Haghjoo M, Ayra A, Heidari A, Sadr-Ameli MA: Supresión of electrical storm by oral quinidine in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2005;16:674.
30. Márquez MF, Rivera J, Hermosillo AG, Iturralde P, Colín L, Moragrega JL, Cárdenas M: Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope. Pacing Clin Electrophysiol 2005;28:870-874.
31. RuDusky BM: Cholestyramine therapy for quinidine-induced diarrhea. Case reports. Angiology 1997;2:173-176.
32. Vidaurri A, Pastelín G, Méndez R, Cárdenas M: El tratamiento de la fibrilación auricular con infusión intravenosa de quinidina. Arch Inst Cardiol Mex 1983;53:5-11.
33. Bigger JT, Hoffman BF: Antiarrhythmic drugs. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1992, pp. 848-857.
34. Kasanuki H, Ohnishi S, Ohtusa M, Matsuda N, Nirei T, Isogai R, Soda M, Toyoshima Y, Hosoda S: Idiopathic ventricular fibrillation induced witch vagal activity in patients without obvious heart disease. Circulation 1997;95:2277-2285.
35. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S: Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996;27:1061-1070.
36. Shimizu W, Matsuo K, Takagi M, Tanabe Y, Aiba T, Taguchi A, Suyama K, Kurita T, Aihara N, Kamakura S: Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: Clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 2000;11:396-404.
37. Tanaka H, Kinoshita O, Uchikawa S, Kasai H, Nakamura M, Izawa A, Yokoseki O, Kitabayashi H, Takahashi W, Yazaki Y, Watanabe N, Imamura H, Kubo K: Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2001;24(8 Pt 1):1293-1294.
38. Maury P, Couderc P, Delay M, Boveda S, Brugada J: Electrical storm in Brugada syndrome successfully treated using isoprenaline. Europace 2004;6:130-133.
39. Suzuki H, Torigoe K, Numata O, Yazaki S: Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol 2000;11:1277-1280.
40. Silva RM, Mont L, Nava S, Rojel U, Matas M, Brugada J: Radiofrequency catheter ablation for arrhythmic storm in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2004;27:971-975.
41. Aouate P, Clerc J, Viard P, Seoud J: Propanolol intoxication revealing Brugada syndrome. J Cardiovasc Electrophysiol 2005;16:348-351.
42. Nademanee K, Vaeerakul G, Mower M, Likittanasombat K, Krittayapong R, Bhuripanyo K, Sitthisook S, Chaothawee L, Lai Yin M, Azen S: Defibrillator versus β-blockers for unexplained death in Thailand (DEBUT) a randomized clinical trial. Circulation 2003; 107:2221-2226.
43. Glatter KA, Wang Q, Keating M, Chen S, Chiamvimonvat N, Scheinman MM: Effectiveness of sotalol treatment in symptomatic Brugada syndrome. Am J Cardiol 2004;93:1320-1322.
44. Bertaglia E, Michieletto M, Speciato L, Pascotto P: Right bundle branch block, intermittent ST segment elevation and inducible ventricular tachycardia in an asymptomatic patient: An unusual presentation of the Brugada syndrome? G Ital Cardiol 1998;28:893-898.
45. Kabela E, Pastelin G, Scheffner L, Sánchez Pérez S, Méndez R: Studio sperimentale sulla disopirimide come antiarritmico. Minerva Med 1970;61:3694-3706.
46. Belhassen B, Shapira I, Shoshani D, Paredes A, Miller H, Laniado S: Idiopathic ventricular fibrillation: Inducibility and beneficial effects of class I antiarrhythmic agents. Circulation 1987;75:809-816.
47. Yan GX, Antzelevitch C: Cellular basis for the Brugada síndrome and other mechanisms of arrhythmogenesis associated UIT ST-segment elevation. Circulation 1999;100:1660-1666
48. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology: The 'Sicilian Gambit.' A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J 1991;12:1112-1131.
49. Jewitt D: Clinical electrophysiological effects of Mexiletine. In: Sandoe E, Julian DG, Bell JW, eds. Management of Ventricular Tachycardia. Role of mexiletine. Excerpta Medica: Amsterdam, 1978, pp. 237-246.
50. Doggrell SA: Tedisamil: Master switch of nature? Expert Opin Investig Drugs 2001;10:129-138.
51. Fox KM, Henderson JR, Kaski JC, Sachse A, Kuester L, Wonnacott S: Antianginal and anti-ischaemic efficacy of tedisamil, a potassium channel blocker. Heart 2000;83:167-171.
52. Wallace AA, Stupienski III RF, Baskin EP, Appleby SD, Kothstein T, Gehret JR, King SW, Remy DC, Lynch JJ Jr: Cardiac electrophysiologic and antiarrhythmic actions of tedisamil. J Pharmacol Exp Ther 1995;273:168-175.
53. + current blocker. Br J Pharmacol 1991;102:13-18.
54. Nemeth M, Varro A, Virag L, Hacutela O, Thormahlen D, Papp JG: Frequency-dependent cardiac electrophysiologic effects of tedisamil: Comparison with quinidine and sotalol. J Cardiovasc Pharmacol Ther 1997;2:273-284.
55. Wettwer E, Himmel HM, Amos GJ, Li Q, Metzger F, Ravens U: Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br J Pharmacol 1998;125:659-666.
56. Hohnloser SH, Dorian P, Straub M, Beckmann K, Kowey P: Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol 2004;44:99-104.
57. Salaices M, Alonso MJ: Introducción a la farmacologcia del sistema nervioso autónomo. Generalidades. Neurotransmisión colinérgica. Farmacología ganglionar y de la placa motora. In: Lorenzo P, Moreno A, Leza JC, Lizasoain I, Moro MA, eds. Velásquez. Farmacología Básica y Clínica. Editorial Médica Panamericana: Madrid, 2005, pp. 99-120.
58. Campbell DL, Qu Y, Rasmusson RL, Strauss HC: The calciumin-dependent transient outward potassium current in isolated ferret right ventricular myocytes. II. Closed state reverse use-dependent block by 4-aminopyridine. J Gen Physiol 1993;101:603-626.
59. Lukas A, Antzelevitch C: Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia. Cardiovasc Res 1996;32:593-603.
60. Magdalan J: New treatment methods in verapamil poisoning: Experimental studies. Pol J Pharmacol 2003;55:425-432.
61. Gluais P, Bastide M, Grandmougin D, Fayad G, Adamantidis M: Clarithromycin reduces Isus and Ito currents in human atrial myocytes with minor repercussions on action potential duration. Fundam Clin Pharmacol 2003;17:691-701.
62. Teerlink JR, Jalaluddin M, Anderson S, Kukin ML, Eichhorn EJ, Francis G, Packer M, Massie BM: Ambulatory ventricular arrhythmias in pàtients with heart failure do not specifically predict and increased risk of sudden death. Circulation 2000;101:40-46.